Prognostic assessment of sarcomatous histologic subtypes of ovarian carcinosarcoma.
10.5468/ogs.2017.60.4.350
- Author:
Hyun Jin KIM
1
;
Hyun Mi LEE
;
Mi Kyung KIM
;
Yoo Kyung LEE
;
In Ho LEE
;
Ki Heon LEE
;
Hyesun KIM
Author Information
1. Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Dankook University College of Medicine, Seoul, Korea. yookyunglee75@gmail.com
- Publication Type:Original Article
- Keywords:
Carcinosarcoma;
Histology;
Ovarian neoplasms;
Prognosis
- MeSH:
Carcinosarcoma*;
Chemotherapy, Adjuvant;
Classification;
Delivery of Health Care;
Disease-Free Survival;
Gynecology;
Hospitals, General;
Humans;
Medical Records;
Multivariate Analysis;
Ovarian Neoplasms;
Prognosis;
Recurrence
- From:Obstetrics & Gynecology Science
2017;60(4):350-356
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: Ovarian carcinosarcoma is a rare subtype of this disease that has not been thoroughly investigated. The aim of this study was to evaluate the prognostic factors and out comes in patients with ovarian carcinosarcoma. METHODS: All patients with histologically confirmed ovarian carcinosarcoma who were treated at Cheil General Hospital and Women's Healthcare Center between January 2000 and December 2015 were identified and analyzed. Data were extracted from medical records, and statistical analyses were performed to determine correlations between clinicopathological parameters and survival outcomes. RESULTS: Of the 822 patients diagnosed with ovarian cancer over 16 years, 11 (1.3%) had ovarian carcinosarcoma histology. Every patient underwent surgery as the initial treatment followed by intravenous adjuvant chemotherapy. Only 18.1% of cases were early stage (I or II) while 81.8% were advanced stage (III or IV) according to the FIGO (International Federation of Gynecology and Obstetrics) classification. Six cases were of the homologous subtype (54.5%) and five were of the heterologous subtype (45.5%). There was no significant difference in survival according to stage (P=0.24). The heterologous subtype and residual disease were associated with poor disease-free survival (P=0.02 and P=0.04) and overall survival (P=0.02 and P=0.04), On multivariate analysis, the histological subtype was an independent prognostic factor (P=0.02). CONCLUSION: Optimal cytoreduction without gross residual disease and a homologous subtype are favorable prognostic factors in terms of disease relapse and survival.
